CClinicalTrials.gg
CompletedNCT01234389Updated Dec 14, 2020

Immediate Detection of Helicobacter Infection With a New Electrochemical System.

An interventional study of Electrochemical H. pylori detection method and IHC in H. Pylori Infection, sponsored by University of Erlangen-Nürnberg Medical School. Completed at 1 site in Germany. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-14.

Sponsored by University of Erlangen-Nürnberg Medical School · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Oct 2009, registered Nov 2010).
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Helicobacter pylori-infection (H. pylori) affects about fifty percent of the general population and is associated with peptic ulcer disease, non-cardia gastric adenocarcinoma and gastric lymphoma. Currently, diagnostic methods include breath tests, serology, stool antigen tests, histology or the Helicobacter urease test (HUT).

The aim of our study is to access the clinical reliability of a new, electrochemical device for rapid H. pylori detection.

Read the detailed description

The newly developed electrochemical device for H. pylori detection consists of a working and reference electrode between which a biopsy sample is administered. Afterwards, acquired voltage-values could be analysed for characteristics typical for H. pylori infection (ammonia). According to Sydney classification, biopsies are taken from gastric antrum and corpus for electrochemical H. pylori detection, HUT and immunohistochemistry (IHC). HUT results are evaluated after 24 hours. Furthermore, every patient will receive 13C-urea breath test. IHC is designated as the gold standard of H. pylori diagnosis.

02

Conditions studied

03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 120 is close to the median of 120 across 4,200 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

University of Erlangen-Nürnberg Medical School is the lead sponsor of 267 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Written informed consent
  • Age 18-85 years
  • Ability of subjects to understand character and individual consequences of clinical trial
  • Subjects undergoing EGD

Exclusion criteria

Exclusion Criteria:

  • Inability to provide written informed consent
  • Severe Coagulopathy (Prothrombin time \< 50% of control, Partial thromboplastin time > 50 s)
  • Pregnancy or breast feeding
  • Active gastrointestinal bleeding
  • Residing in institutions (e.g. prison)
  • PPI intake
  • antibiotic use, actual or within the last 4 weeks
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Other
    H. pylori positive patients

    Device: Electrochemical H. pylori detection method · Device: IHC · Device: C13-urea breath test · Device: HUT

  • Other
    H. pylori negative patients

    Device: Electrochemical H. pylori detection method · Device: IHC · Device: C13-urea breath test · Device: HUT

Interventions

  • DeviceElectrochemical H. pylori detection method

    Determination of H. pylori infection.

  • DeviceIHC

    Determination of H. pylori infection.

    Also known as: Determination of H. pylori infection.

  • DeviceC13-urea breath test

    Determination of H. pylori infection.

  • DeviceHUT

    Determination of H. pylori infection.

06

What researchers measure

Primary outcomes

  1. Effectiveness of the newly developed device in comparison to IHC, HUT and C13-urea breath test.

    Time frame: Oktober 2009 - February 2011

07

Study locations

1 site
  • University of Erlangen-Nuremberg
    Erlangen, Bayern 91054, Germany
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01234389
Lead sponsor
University of Erlangen-Nürnberg Medical School
Responsible party
Sponsor
First posted
Nov 4, 2010
Start date
Oct 2009
Primary completion
Jan 2013
Completion
Jan 2013
Last update
Dec 14, 2020

Study contacts

Markus F. Neurath, M.D., Ph.D.
study director · University of Erlangen-Nürnberg
Helmut Neumann, M.D., Ph.D.
principal investigator · University of Erlangen-Nürnberg

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion